There is an interesting research which states that apixaban is a much better drug of choice than Rivaroxaban in adults with atrial fibrillation (AF) on starting a direct oral anticoagulant (DOAC) for stroke prevention.
Atrial fibrillation incidence has increased in aged populations worldwide, and increased survival with chronic diseases.
United States alone, reported atleast 3 to 6 million people have atrial fibrillation, and the numbers are projected to reach 6 to 16 million by 2050 approximately. In Europe, prevalent atrial fibrillation in 2010 was 9 million among individuals older than 55 years and is expected to reach 14 million by 2060.
It is estimated that by 2050 atrial fibrillation will be diagnosed at least in 72 million individuals in Asia, approximately 3 million with atrial fibrillation related strokes.